Whitepapers

Payers have influence at a number of points across a brand's lifecycle. Understanding and managing the impact of this influence is key to unlocking an intervention's commercial potential. We've created a roadmap that outlines the different stages that payers can influence and outlines strategic considerations for brand teams.

You will have likely seen recently that inappropriate use of Microsoft Excel® has led to a major issue with the UK’s Test and Trace system, with the reporting of almost 16,000 positive COVID-19 cases being delayed for over a week due to CSV row number limitations.1 The heart of the issue is the use of Excel to transfer data between one system and another – and, more generally, continuing to use outdated software versions and antiquated methods to transfer data, rather than creating systems that truly talk to each other and operate within the same framework (i.e. that are capable of record storage as well as the powerful analytical analysis required to perform country-wide pandemic modelling).

The ToxicoGenomica team has brought genomic causation analysis into over 30 cancer cases for defendants in cases involving benzene, radiation, and asbestos (see here for a description of five of the older cases).